Applied Therapeutics Past Performance
Past criteria checks 0/6
Applied Therapeutics's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 171.3% per year.
Earnings growth rate
EPS growth rate
|Biotechs Industry Growth||32.1%|
|Revenue growth rate||171.3%|
|Return on equity||n/a|
|Last Earnings Update||31 Mar 2023|
Recent past performance updates
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn RateMay 19
Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's StockJan 19
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?Nov 11
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn SituationAug 13
Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorderJun 17
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?May 15
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)Feb 26
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?Feb 18
Applied Therapeutics to resume galactosemia study for AT-007Feb 02
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been SellingNov 24
Applied Therapeutics EPS misses by $0.21Nov 12
Earnings and Revenue History
Quality Earnings: APLT is currently unprofitable.
Growing Profit Margin: APLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APLT is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare APLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Return on Equity
High ROE: APLT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.